Results 31 to 40 of about 29,559 (188)

Outcomes of MIS-C patients treated with anakinra: a retrospective multicenter national study

Frontiers in Pediatrics, 2023
BackgroundThe treatment of multisystem inflammatory syndrome in children unresponsive to first-line therapies (IVIG and/or steroids) is challenging. The effectiveness of IL-1 receptor antagonist, anakinra, is debated.Patients and methodsWe conducted an ...
Francesco Licciardi, Carlotta Covizzi, Marta Dellepiane, Nicole Olivini, Maria Vincenza Mastrolia, Andrea Lo Vecchio, Viviana Monno, Maria Tardi, Angela Mauro, Maria Alessio, Giovanni Filocamo, Marco Cattalini, Andrea Taddio, Roberta Caorsi, Gian Luigi Marseglia, Francesco La Torre, Andrea Campana, Gabriele Simonini, Angelo Ravelli, Davide Montin   +19 more
doaj   +1 more source

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]

, 2016
Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet, Bhatia, Ravi, Campbell, Victoria L., Chu, Su, Gaal, Karl, Holyoake, Tessa L., Hopcroft, Lisa, Jørgensen, Heather G., Lin, Allen, Zhang, Bin   +9 more
core   +1 more source

Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study

Critical Care, 2020
Background A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases.
Emma J. Kooistra, Nicole J. B. Waalders, Inge Grondman, Nico A. F. Janssen, Aline H. de Nooijer, Mihai G. Netea, Frank L. van de Veerdonk, Esther Ewalds, Johannes G. van der Hoeven, Matthijs Kox, Peter Pickkers, the RCI-COVID-19 Study Group   +11 more
doaj   +1 more source

Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease [PDF]

, 2018
Adult-onset Still's disease (AOSD) is a rare inflammatory disease of unknown etiology typically characterized by episodes of spiking fever, evanescent rash, arthralgia, leukocytosis, and hyperferritinemia. The pivotal role of interleukin (IL)-1 and other
Baggio, Chiara, Bindoli, S, Galozzi, P, Oliviero, F, Sfriso, P   +4 more
core   +1 more source

Reimann's "Habitual Hyperthermia" Responding to Hormone Therapy. [PDF]

, 2016
A 25-year-old woman presented with fever of unknown origin, exhibiting malaise and low-grade fevers in evenings. These fevers exhibited a pattern of starting mid-menstrual cycle with resolution around the onset of menses, matching a pattern of "habitual ...
Currier, Judith S, Yang, Otto O
core   +2 more sources

Anakinra [PDF]

Reactions Weekly, 2021
  +5 more sources

IL-1 Receptor Antagonist Anakinra Inhibits the Effect of IL-1β- Mediated Osteoclast Formation by Periodontal Ligament Fibroblasts

Biology
Rheumatoid arthritis and periodontitis are comorbidities that share mutual pathways. IL-1β is a pro-inflammatory cytokine that plays a crucial role in both diseases.
Elizabeth Steemers, Wael M. I. Talbi, Jolanda M. A. Hogervorst, Ton Schoenmaker, Teun J. de Vries   +4 more
doaj   +1 more source

Expedited Desensitization to Canakinumab

Allergy & Rhinology, 2020
Introduction Interleukin-1 (IL-1) antagonists have been successful in the management of monogenic auto-inflammatory diseases, notably classic hereditary fever syndromes, such as Familial Mediterranean Fever (FMF). Anakinra (Kineret®), a human recombinant
Neha Sanan DO, Jason Schend DO, Marija Rowane OMS-III, Robert Hostoffer DO, FAAFP, FACOP   +3 more
doaj   +1 more source

Molecular Predictors of Anakinra Treatment Success in Heart Failure Patients with Reduced Ejection Fraction [PDF]

, 2020
Background. Kineret (Anakinra) is an interleukin-1 antagonist that is under investigation for its novel clinical application treating patients that have heart failure with reduced (\u3c50%) ejection fraction (HFrEF).
Abbate, Antonio, Alshammari, Suad, Alsultan, Monther, Buckley, Leo F., Canada, Justin M, Carbone, Salvatore, Contaifer, Daniel, Jr, Morriss, Joshua, Price, Elvin T., Ranasinghe, Asanga D., Trankle, Cory, Van Tassell, Benjamin W., Wijesinghe, Dayanjan S, Wohlford, George   +13 more
core   +1 more source

New insights into the impact of neuro-inflammation in rheumatoid arthritis. [PDF]

, 2014
Rheumatoid arthritis (RA) is considered to be, in many respects, an archetypal autoimmune disease that causes activation of pro-inflammatory pathways resulting in joint and systemic inflammation.
Akasbi, Alten, Askling, Axford, Barrick, Bean, Bekkelund, Bongartz, Burmester, Burmester, Capellino, Cheng, Chiu, Chou, Combs, De Almeida, De Rycke, Detrait, Diamond, Doran, Doran, Emmer, Fayed, Feldmann, Firestein, Franklyn A. Howe, Germano, Gregersen, Gussew, Hamed, Harris, Ho, Hull, Hunter, Inan, Jacobs, Kaltsonoudis, Keane, Keystone, King, Klareskog, Lauvsnes, Lee, Leombruno, Lipsky, Listing, MacGregor, Mahdi, Malaviya, Markenson, McInnes, Medeiros, Mellor, Meseguer, Mikuls, Morris, Nadeau, Ni Mhuircheartaigh, Nicholas R. Fuggle, Nidhi Sofat, Nishioku, Norheim, O'Callaghan, Ogawa, Panayi, Parks, Rachel L. Allen, Ramiro, Rech, Rosenblum, Salliot, Salmon-Ceron, Scher, Schoels, Schweinhardt, Scott, Senaldi, Serrats, Skelly, Smolen, Sokka, Steens, Strangfeld, Symmons, Taylor, Teeling, Thomson, Tracey, Tubach, Upadhyay, van der Woude, van Heemst, van Vollenhoven, Vincent, Wallis, Wartolowska, Wegner, Wellcome Trust Case Control Consortium., Wendler, Weyand, Wolfe, Woolf, Zivadinov   +102 more
core   +2 more sources